REGN Jan 2025 960.000 put
OPR - OPR Delayed price. Currency in USD
Add to watchlist
As of 10:08AM EDT. Market open.
| Previous close | 70.59 |
| Open | 60.00 |
| Bid | 52.50 |
| Ask | 58.30 |
| Strike | 960.00 |
| Expiry date | 2025-01-17 |
| Day's range | 60.00 - 60.00 |
| Contract range | N/A |
| Volume | |
| Open interest | 33 |
Simply Wall St.Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) large institutional owners must be happy as stock continues to impress, up 3.2% over the past week
Key Insights Institutions' substantial holdings in Regeneron Pharmaceuticals implies that they have significant...
- Thomson Reuters StreetEvents
Q1 2024 Intellia Therapeutics Inc Earnings Call
Q1 2024 Intellia Therapeutics Inc Earnings Call
GlobeNewswireLatest DB-OTO Results Show Dramatically Improved Hearing to Normal Levels in a Child with Profound Genetic Deafness within 24 Weeks and Initial Hearing Improvements in a Second Child at 6 Weeks
Preliminary data detailed in an ASGCT oral presentation include results for one of the youngest children in the world to receive a gene therapy for genetic deafness Ongoing Phase 1/2 CHORD trial is currently enrolling infants and children in the U.S., UK and Spain TARRYTOWN, N.Y., May 08, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the investigational gene therapy DB-OTO improved hearing to normal levels in one child (dosed at 11 months of age) wi
© 2024 Yahoo. All rights reserved.